Author:
Li Jenny J.,Kovach Alexander R.,DeMonia Margaret,Slemmons Katherine K.,Oristian Kristianne M.,Chen Candy,Linardic Corinne M.
Abstract
AbstractRhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. The two predominant histologic variants of RMS, embryonal and alveolar rhabdomyosarcoma (eRMS and aRMS, respectively), carry very different prognoses. While eRMS is associated with an intermediate prognosis, the 5-year survival rate of aRMS is less than 30%. The RMS subtypes are also different at the molecular level—eRMS frequently has multiple genetic alterations, including mutations in RAS and TP53, whereas aRMS often has chromosomal translocations resulting in PAX3-FOXO1 or PAX7-FOXO1 fusions, but otherwise has a “quiet” genome. Interestingly, mutations in RAS are rarely found in aRMS. In this study, we explored the role of oncogenic RAS in aRMS. We found that while ectopic oncogenic HRAS expression was tolerated in the human RAS-driven eRMS cell line RD, it was detrimental to cell growth and proliferation in the human aRMS cell line Rh28. Growth inhibition was mediated by oncogene-induced senescence and associated with increased RB pathway activity and expression of the cyclin-dependent kinase inhibitors p16 and p21. Unexpectedly, the human eRMS cell line RMS-YM, a RAS wild-type eRMS cell line, also exhibited growth inhibition in response to oncogenic HRAS in a manner similar to aRMS Rh28 cells. This work suggests that oncogenic RAS is expressed in a context-dependent manner in RMS and may provide insight into the differential origins and therapeutic opportunities for RMS subtypes.
Funder
Alex's Lemonade Stand Foundation for Childhood Cancer
V Foundation for Cancer Research
National Institutes of Health
Glenn and Stacy Schiffman Pediatric Cancer Research Fund
Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. Ries, L. et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. NIH Pub. No. 99-4649 (National Cancer Institute, SEER Program, 1999).
2. Ognjanovic, S., Linabery, A. M., Charbonneau, B. & Ross, J. A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States (1975–2005). Cancer 115, 4218–4226. https://doi.org/10.1002/cncr.24465 (2009).
3. Crist, W. M. et al. Prognosis in children with rhabdomyosarcoma: A report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J. Clin. Oncol. 8, 443–452 (1990).
4. Chen, X. et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24, 710–724. https://doi.org/10.1016/j.ccr.2013.11.002 (2013).
5. Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. https://doi.org/10.1158/2159-8290.cd-13-0639 (2014).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献